UA75053C2 - Substituted pyridines and pyridazines able to inhibit angiogenesis - Google Patents

Substituted pyridines and pyridazines able to inhibit angiogenesis Download PDF

Info

Publication number
UA75053C2
UA75053C2 UA2002043504A UA2002043504A UA75053C2 UA 75053 C2 UA75053 C2 UA 75053C2 UA 2002043504 A UA2002043504 A UA 2002043504A UA 2002043504 A UA2002043504 A UA 2002043504A UA 75053 C2 UA75053 C2 UA 75053C2
Authority
UA
Ukraine
Prior art keywords
amino
alkyl
methyl
substituted
optionally substituted
Prior art date
Application number
UA2002043504A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UA75053C2 publication Critical patent/UA75053C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
UA2002043504A 1999-09-28 2000-09-26 Substituted pyridines and pyridazines able to inhibit angiogenesis UA75053C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
UA75053C2 true UA75053C2 (en) 2006-03-15

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002043504A UA75053C2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines able to inhibit angiogenesis

Country Status (36)

Country Link
EP (1) EP1228063B1 (ru)
JP (1) JP4919567B2 (ru)
KR (3) KR100895571B1 (ru)
CN (3) CN100374435C (ru)
AR (3) AR025752A1 (ru)
AT (1) ATE422494T1 (ru)
AU (1) AU782820B2 (ru)
BG (1) BG65860B1 (ru)
BR (1) BRPI0014382B8 (ru)
CA (1) CA2385817C (ru)
CO (1) CO5200835A1 (ru)
CZ (1) CZ304767B6 (ru)
DE (1) DE60041548D1 (ru)
DO (1) DOP2000000070A (ru)
EE (1) EE05258B1 (ru)
ES (1) ES2320525T3 (ru)
GT (1) GT200000158A (ru)
HK (2) HK1091818A1 (ru)
HR (1) HRP20020308A2 (ru)
HU (1) HU230223B1 (ru)
IL (3) IL148880A0 (ru)
MA (1) MA25563A1 (ru)
MX (1) MXPA02003156A (ru)
MY (3) MY143580A (ru)
NO (1) NO20021520L (ru)
NZ (1) NZ518589A (ru)
PA (1) PA8503201A1 (ru)
PE (1) PE20010607A1 (ru)
PL (1) PL205957B1 (ru)
RS (1) RS50369B (ru)
RU (1) RU2260008C2 (ru)
SK (1) SK287417B6 (ru)
TW (1) TW593315B (ru)
UA (1) UA75053C2 (ru)
WO (1) WO2001023375A2 (ru)
ZA (1) ZA200202760B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004505965A (ja) * 2000-08-09 2004-02-26 アストラゼネカ アクチボラグ 化合物
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
PT1603566E (pt) * 2003-03-11 2009-04-27 Novartis Ag Utilização de derivados de isoquinolina para tratamento de cancro e de doenças relacionadas com map-cinase
EP1616576A4 (en) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE INHIBITOR
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
CA2648957A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
HU219864B (hu) * 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
BR0009507A (pt) * 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Also Published As

Publication number Publication date
AU782820B2 (en) 2005-09-01
YU22902A (sh) 2004-12-31
HK1091819A1 (en) 2007-01-26
HU230223B1 (en) 2015-10-28
KR100895572B1 (ko) 2009-04-29
MY135058A (en) 2008-01-31
RU2260008C2 (ru) 2005-09-10
AR082231A2 (es) 2012-11-21
HUP0202704A3 (en) 2003-12-29
IL193368A (en) 2011-05-31
KR20080091505A (ko) 2008-10-13
CN100422172C (zh) 2008-10-01
CO5200835A1 (es) 2002-09-27
CZ304767B6 (cs) 2014-10-08
CZ20021444A3 (cs) 2002-08-14
JP2003526632A (ja) 2003-09-09
SK287417B6 (sk) 2010-09-07
TW593315B (en) 2004-06-21
HRP20020308A2 (en) 2004-06-30
IL193368A0 (en) 2009-02-11
IL193367A (en) 2011-03-31
SK5912002A3 (en) 2003-01-09
MA25563A1 (fr) 2002-10-01
CA2385817A1 (en) 2001-04-05
PL366342A1 (en) 2005-01-24
AU1569601A (en) 2001-04-30
WO2001023375A3 (en) 2002-05-02
CN100374435C (zh) 2008-03-12
EP1228063B1 (en) 2009-02-11
BR0014382A (pt) 2003-06-24
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
KR100890473B1 (ko) 2009-03-26
BG65860B1 (bg) 2010-03-31
NZ518589A (en) 2005-03-24
ES2320525T3 (es) 2009-05-25
GT200000158A (es) 2002-03-16
CN1420879A (zh) 2003-05-28
BR0014382B1 (pt) 2014-04-01
KR20020038775A (ko) 2002-05-23
EE05258B1 (et) 2010-02-15
BRPI0014382B8 (pt) 2021-05-25
ZA200202760B (en) 2003-10-29
HRP20020308B1 (ru) 2013-01-31
ATE422494T1 (de) 2009-02-15
NO20021520L (no) 2002-05-23
PA8503201A1 (es) 2002-08-26
KR100895571B1 (ko) 2009-04-29
DE60041548D1 (de) 2009-03-26
MXPA02003156A (es) 2002-09-30
CN1769283A (zh) 2006-05-10
JP4919567B2 (ja) 2012-04-18
PL205957B1 (pl) 2010-06-30
HK1091818A1 (en) 2007-01-26
DOP2000000070A (es) 2002-02-28
KR20080086547A (ko) 2008-09-25
AR025752A1 (es) 2002-12-11
NO20021520D0 (no) 2002-03-26
MY143580A (en) 2011-05-31
EE200200161A (et) 2003-08-15
RS50369B (sr) 2009-11-10
BG106637A (bg) 2003-02-28
HUP0202704A2 (hu) 2002-12-28
PE20010607A1 (es) 2001-07-12
IL193367A0 (en) 2009-02-11
MY143377A (en) 2011-05-13
IL148880A0 (en) 2002-09-12
AR082232A2 (es) 2012-11-21
CA2385817C (en) 2010-05-04
CN100422173C (zh) 2008-10-01
WO2001023375A2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
UA75053C2 (en) Substituted pyridines and pyridazines able to inhibit angiogenesis
ES2968810T3 (es) Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP6141866B2 (ja) 置換ベンジルピラゾール類
CN104520290A (zh) 酰氨基螺环酰胺和磺酰胺衍生物
JP2016514719A (ja) ヘテロアリール置換インダゾール
JP2015520143A (ja) 癌を治療するためのbub1阻害薬としての置換されているシクロアルケノピラゾール類
CN104507936A (zh) 吡啶基和嘧啶基亚砜和砜衍生物
JP2016525076A (ja) 置換されたベンジルピラゾール類
WO2007037534A1 (ja) 2-へテロアリール置換インドール誘導体
JP2003522773A (ja) 血管形成および/またはvegf受容体チロシンキナーゼを阻害するピリジン誘導体
TW200829589A (en) Compound for inhibiting mitotic progression
CN110372669A (zh) 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用
CN104603134A (zh) 酰氨基-苄基砜和亚砜衍生物
EA018964B1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
JP6850361B2 (ja) キナーゼを選択的に阻害する化合物及びその使用
AU775237B2 (en) Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
US6689883B1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US20110263597A1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
WO2017034242A2 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
EP2646445B1 (en) Oxazolo[5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
WO2010131738A1 (ja) アゼチジン化合物およびその医薬用途
CN109134431B (zh) 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物
JP2005533109A (ja) 高増殖性障害の処置のためのフロピリジン及びフロピリミジン誘導体
CN117756812A (zh) 一类prmt5抑制剂及其用途
JP2023538774A (ja) 新規な選択的flt3阻害剤としての1h-イミダゾ[4,5-h]キナゾリン化合物